Comparison of efficacy and safety of sitagliptin or ipragliflozin in type 2 diabetic patients with insulin therapy

Comparison of efficacy and safety of sitagliptin or ipragliflozin in type 2 diabetic patients with insulin therapy - Administration of sitagliptin or ipragliflozin in type 2 diabetic patients with insulin therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014139

Enrollment

Registered

2014-06-03

Start date

2014-06-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Treatment with ipraglifrozin. Treatment with sitagliptin.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have HbA1c levels 7 or more %

Exclusion criteria

Exclusion criteria: Patients whose BMI is less than 18 Patients with moderale renal disfunction Patients with sever liver disfunction Patients who have experienced severe diabetic ketosis, diabetic coma, or past history of pre-coma prior to 3 months Patients with sever infection, operation, trauma, and urine and genital infection Female patients who have pregnancy or possibilty of pregnancy, or are under lactation Patients who are considered to be not eligible to the study by the doctor

Design outcomes

Primary

Measure	Time frame
HbA1c(non-inferiority margin is 0.4%)	—

Countries

Japan

Contacts

Public ContactYoshihiko Noguchi

Yokohama City University Department of Endocrinology and Metabolism

nikukyu79@yahoo.co.jp045-787-2369

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026